MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate

Pharmaceutical Research

Volumn 31, Issue 5, 2014, Pages 1120-1132

  Liu, Qi ^a   Wang, Changyuan ^a   Meng, Qiang ^a   Huo, Xiaokui ^a   Sun, Huijun ^a   Peng, Jinyong ^a   Ma, Xiaochi ^a   Sun, Pengyuan ^a   Liu, Kexin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

drug drug interaction; MDR1; methotrexate; OATs; puerarin

Indexed keywords

DIGOXIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PUERARIN; ABCB1 PROTEIN, HUMAN; ISOFLAVONE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG POTENTIATION; DRUG TRANSPORT; HEK293 CELL LINE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MDCK CELL LINE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCYTOSIS; URINARY EXCRETION; ANIMAL; CELL LINE; DOG; DRUG INTERACTION; LIQUID CHROMATOGRAPHY; PHYSIOLOGY; TANDEM MASS SPECTROMETRY; WISTAR RAT;

ANIMALS; CELL LINE; CHROMATOGRAPHY, LIQUID; DOGS; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; ISOFLAVONES; MALE; METHOTREXATE; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEINS; RATS; RATS, WISTAR; TANDEM MASS SPECTROMETRY;

EID: 84902287467     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1235-9     Document Type: Article

References (40)

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
2. Cruz-Munoz W, Man S, Kerbel RS. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res. 2009;15(15):4867-74.
3. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol. 2009;20(8):1402-7.
4. Guo X, Meng Q, Liu Q, Wang C, Mao Q, Sun H, et al. Peptide cotransporter 1 in intestine and organic anion transporters in kidney are targets of interaction between JBP485 and lisinopril in rats. Drug Metab Pharmacokinet. 2012;27(2):232-41.
5. Ye J, Liu Q, Wang C, Meng Q, Peng J, Sun H, et al. Inhibitory effect of JBP485 on renal excretion of acyclovir by the inhibition of OAT1 and OAT3. Eur J Pharm Sci. 2012;47(2):341-6.
6. US Food and Drug Administration. Draft guidance for industry: Drug interaction studies-study design, data analysis, and implications for dosing and labeling. 2012 (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf).
7. Zhang L, Zhang YD, Zhao P, Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11(2):300-6.
8. Zhang J, Wang C, Liu Q, Meng Q, Cang J, Sun H, et al. Pharmacokinetic interaction between JBP485 and cephalexin in rats. Drug Metab Dispos. 2010;38(6):930-8.
9. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3-29.
10. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci. 2006;27(1):17-24.
11. Masereeuw R, Russel FG. Therapeutic implications of renal anionic drug transporters. Pharmacol Ther. 2010;126(2):200-16.
12. Maeda A, Tsuruoka S, Kanai Y, Endou H, Saito K, Miyamoto E, et al. Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporters 3-transfected cells. Eur J Pharmacol. 2008;596(1-3):166-72.
13. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645-8.
14. Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer. 2012;118(17):4321-30.
15. Yang G, Li X, Li X, Wang L, Li J, Song X, et al. Traditional chinese medicine in cancer care: a review of case series published in the chinese literature. Evid Based Complement Alternat Med. 2012;2012:751046.
16. Zhang J, Zhou F, Wu X, Gu Y, Ai H, Zheng Y, et al. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions. Drug Metab Dispos. 2010;38(12):2179-87.
17. Liu CM, Ma JQ, Sun YZ. Puerarin protects rat kidney from lead-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Toxicol Appl Pharmacol. 2012;258(3):330-42.
18. Liang XL, Zhao LJ, Liao ZG, Zhao GW, Zhang J, Chao YC, et al. Transport properties of puerarin and effect of Radix Angelicae Dahuricae extract on the transport of puerarin in Caco-2 cell model. J Ethnopharmacol. 2012;144(3):677-82.
19. Yang AK, He SM, Liu L, Liu JP, Wei MQ, Zhou SF. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem. 2010;17(16):1635-78.
20. Miao Q, Liu Q, Wang C, Meng Q, Guo X, Sun H, et al. Inhibitory effect of 1α,25-dihydroxyvitamin D(3) on excretion of JBP485 via organic anion transporters in rats. Eur J Pharm Sci. 2012;48(1-2):351-9.
21. Liu Z, Wang C, Liu Q, Meng Q, Cang J, Mei L, et al. Uptake, transport and regulation of JBP485 by PEPT1 in vitro and in vivo. Peptides. 2011;32(4):747-54.
22. Zhu Y, Meng Q, Wang C, Liu Q, Sun H, Kaku T, et al. Organic anion transporters involved in the excretion of bestatin in the kidney. Peptides. 2012;33(2):265-71.
23. Guo P, Wang X, Liu L, Belinsky MG, Kruh GD, Gallo JM. Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007;43(5):1789-95.
24. Luo CF, Yuan M, Chen MS, Liu SM, Huang BY, Liu XW, et al. Determination of puerarin in rat plasma by rapid resolution liquid chromatography tandem mass spectrometry in positive ionization mode. J Chromatogr B Anal Technol Biomed Life Sci. 2011;879(19):1497-501.
25. Smalley J, Marino AM, Xin B, Olah T, Balimane PV. Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay. J Chromatogr B Anal Technol Biomed Life Sci. 2007;854(1-2):260-7.
26. Fan HY, Lin CC, Pao LH. Determination of p-aminohippuric acid in rat plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(19):1643-6.
27. Liu C, Wang H, Jiang Y, Du Z. Rapid and simultaneous determination of amoxicillin, penicillin G, and their major metabolites in bovine milk by ultra-high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2011;879(7-8):533-40.
28. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther. 2004;311(1):228-36.
29. Joerger M, Huitema AD, van den Bongard HJ, Baas P, Schornagel JH, Schellens JH, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol. 2006;62(1):71-80.
30. Hien TT, Kim HG, Han EH, Kang KW, Jeong HG. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res. 2010;54(7):918-28.
31. Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, et al. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab Dispos. 2011;39(8):1338-44.
32. Paliwal R, Rai S, Vyas SP. Lipid drug conjugate (LDC) nanoparticles as autolymphotrophs for oral delivery of methotrexate. J Biomed Nanotechnol. 2011;7(1):130-1.
33. Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and functions of P-glycoprotein. Curr Med Chem. 2010;17(8):786-800.
34. Li N, Lu M, Chen H, Meng D, Chen Y. Pharmacokinetics of puerarin in patients with diabetic nephropathy. Chin J New Drugs Clin Rem. 2002;21(1):51-3.
35. Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011;39(2):275-82.
36. Ma Z, Wu Q, Lee DY, Tracy M, Lukas SE. Determination of puerarin in human plasma by high performance liquid chromatography. J Chromatogr B Anal Technol Biomed Life Sci. 2005;823(2):108-14.
37. Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. Renal transporters in drug development. Annu Rev Pharmacol Toxicol. 2013;53:503-29.
38. Yan B, Xing D, Ding Y, Tao J, Du LJ. HPLC method for the determination and pharmacokinetic studies on puerarin in cerebral ischemia reperfusion rat plasma after intravenous administration of puerariae radix isoflavone. J Pharm Biomed Anal. 2005;37(2):297-301.
39. Pritchard JB, Sweet DH, Miller DS, Walden R. Mechanism of organic anion transport across the apical membrane of choroid plexus. J Biol Chem. 1999;274(47):33382-7.
40. Abraham P, Kolli VK, Rabi S. Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem Funct. 2010;28(5):426-33.